TCR² plants its flag in for­mer Au­to­lus man­u­fac­tur­ing site, plan­ning to add 175 jobs as it ad­vances lead T cell ther­a­py

Just months af­ter Lon­don-based Au­to­lus Ther­a­peu­tics an­nounced it would let go of 20% of its staffers as it looked for a part­ner for a lead CAR-T pro­gram, the com­pa­ny re­vealed it’s aban­don­ing its Rockville, MD man­u­fac­tur­ing op­er­a­tions.

Au­to­lus’ loss is TCR²’s gain.

The Cam­bridge, MA-based biotech spe­cial­iz­ing in T cell ther­a­pies for on­col­o­gy an­nounced Mon­day it will lease Au­to­lus’ 85,000-square-foot build­ing in an­tic­i­pa­tion of clin­i­cal and com­mer­cial pro­duc­tion of ga­vo-cel. The fa­cil­i­ty is set to go on­line in 2023, TCR² said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER